# Christopher Murphy

> Christopher Murphy is the chief executive officer and a board member of ElevateBio, where he is leading the company's effort to connect genetic-medicine design, process development and commercial manufacturing. His more than 35-year career runs from quality control and vaccine development at American Cyanamid through manufacturing leadership at Sanofi Genzyme, viral-vector scale-up at Brammer Bio and Thermo Fisher Scientific, and a CEO role at Akron Bio. He also serves as board president of Boston youth-development organization West End House.

- **Role:** Chief Executive Officer and Board Member at ElevateBio
- **Organizations:** ElevateBio, Akron Bio, Thermo Fisher Scientific, Brammer Bio, Sanofi Genzyme, BioReliance, American Cyanamid/Wyeth, West End House, MassBioEd Foundation
- **Nationality:** American and Irish
- **Education:** M.S. in Biochemistry, New York Medical College, B.S. in Biological Sciences, Rutgers University - Cook College
- **Known for:** Built more than 35 years of leadership, operational and commercial experience across biopharmaceutical development and manufacturing., Led viral-vector development and manufacturing operations across four Brammer Bio sites before and during the company's growth into Thermo Fisher Scientific., Helped integrate Brammer Bio after Thermo Fisher Scientific acquired it in 2019.

## Career timeline

- **Early career** — Began at American Cyanamid, later Wyeth and now part of Pfizer, in Pearl River, New York, with roles in quality control, viral vaccine development and bulk drug-substance manufacturing.
- **Before 2001** — Led U.S. contract manufacturing operations at BioReliance, focused on viral-vector manufacturing and cell banking.
- **2001-2017** — Held multiple manufacturing and site-leadership roles during a 16-year tenure at Sanofi Genzyme, including work on viral-vector processes, establishment of a clinical gene-therapy facility in San Diego and management of the Allston Landing biologics site.
- **2017** — Joined Brammer Bio as Chief Manufacturing Officer and later served as Chief Operating Officer, leading viral-vector development and manufacturing across four sites.
- **2019** — Moved to Thermo Fisher Scientific with its acquisition of Brammer Bio, helped lead the integration and became Vice President and General Manager of Viral Vector Services.
- **2022** — Appointed Chief Executive Officer of Akron Bio, a supplier of critical inputs for cell and gene therapies.
- **2026** — Appointed Chief Executive Officer and a member of the Board of Directors of ElevateBio on January 5.

## Achievements

- Built more than 35 years of leadership, operational and commercial experience across biopharmaceutical development and manufacturing.
- Led viral-vector development and manufacturing operations across four Brammer Bio sites before and during the company's growth into Thermo Fisher Scientific.
- Helped integrate Brammer Bio after Thermo Fisher Scientific acquired it in 2019.
- Led Akron Bio through a company transformation that ElevateBio says produced revenue and valuation growth.
- Served for a decade with the MassBioEd Foundation and became board chair, supporting science education and workforce development.
- Serves as board president of West End House, which supports more than 1,500 young people in the Boston area.

## Latest updates

- **2026-09** — Shared ElevateBio's participation in Rare Ventures, a Pittsburgh-centered venture-philanthropy collaboration intended to accelerate rare-disease programs through technology, process-development and GMP-manufacturing support.
- **2026-06** — Participated in a Life Sciences Pennsylvania panel on multi-omics, digital health and AI, with ElevateBio highlighting automation and AI as tools for manufacturing bottlenecks.
- **2026-04** — Visited Pittsburgh and discussed BioForge, cost-effective medicine production, artificial intelligence and public incentives for life-sciences manufacturing.
- **2026-03** — Spoke with Pharma Manufacturing about using BaseCamp Pittsburgh as a model for industrializing advanced therapies; the 125,000-square-foot facility is planned to be operational in 2027.
- **2026-01** — Became Chief Executive Officer and a member of ElevateBio's Board of Directors, succeeding interim CEO Ger Brophy.

## Links

- Website: https://elevate.bio/eb-team/chris-murphy/
- LinkedIn: https://www.linkedin.com/in/chriskmurphy
- YouTube: https://youtu.be/XfgIr_BmDB4

---

Profile page: https://yespress.io/christopher-murphy
Published by YesPress — https://yespress.io
Last updated: 2026-09-27